185 related articles for article (PubMed ID: 37358854)
1. Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Meng L; Thapa R; Delgado MG; Gomez MF; Ji R; Knepper TC; Hubbard JM; Wang X; Permuth JB; Kim RD; Laber DA; Xie H
JAMA Netw Open; 2023 Jun; 6(6):e2320035. PubMed ID: 37358854
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Liu X; Ou K; Ma X; Gao L; Wang Q; Zhang H; Yang L
BMC Cancer; 2022 Jul; 22(1):807. PubMed ID: 35864467
[TBL] [Abstract][Full Text] [Related]
3. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405.
Lipsyc-Sharf M; Zhang S; Ou FS; Ma C; McCleary NJ; Niedzwiecki D; Chang IW; Lenz HJ; Blanke CD; Piawah S; Van Loon K; Bainter TM; Venook AP; Mayer RJ; Fuchs CS; Innocenti F; Nixon AB; Goldberg R; O'Reilly EM; Meyerhardt JA; Ng K
J Natl Cancer Inst; 2022 Mar; 114(3):427-435. PubMed ID: 34636852
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Martínez-Lago N; Cameselle García S; Alonso de Castro B; Gómez-Randulfe Rodríguez MI; Carmona Campos M; González Villarroel P; Salgado Fernández M; De la Cámara Gómez JC; Romero Reinoso C; Cousillas Castiñeiras A; Méndez Méndez JC; Vidal Insua Y; Fernández-Montes A
PLoS One; 2022; 17(6):e0269399. PubMed ID: 35657983
[TBL] [Abstract][Full Text] [Related]
6. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M; Tabernero J; Grothey A; Arnold D; O'Dwyer PJ; Gilberg F; Abbas A; Thakur MD; Prizant H; Irahara N; Tahiri A; Schmoll HJ; Van Cutsem E; de Gramont A
Eur J Cancer; 2023 May; 184():137-150. PubMed ID: 36921494
[TBL] [Abstract][Full Text] [Related]
7. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
[TBL] [Abstract][Full Text] [Related]
9. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAF
Shimozaki K; Hirata K; Sato T; Nakamura M; Kato K; Hirano H; Kumekawa Y; Hino K; Kawakami K; Kito Y; Matsumoto T; Kawakami T; Komoda M; Nagashima K; Sato Y; Yamazaki K; Hironaka S; Takaishi H; Hamamoto Y; Muro K
Clin Colorectal Cancer; 2022 Dec; 21(4):339-346. PubMed ID: 36117091
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.
Taieb J; Lonardi S; Desai J; Folprecht G; Gallois C; Marques EP; Khan S; Castagné C; Wasan H
Clin Colorectal Cancer; 2023 Mar; 22(1):59-66. PubMed ID: 36653241
[TBL] [Abstract][Full Text] [Related]
11. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Jun; 18(2):110-115.e2. PubMed ID: 30679026
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Raga MG; Pérez IP; Veiga RC; Sosa MM; Aguilera MJS; Rodríguez PL; Bonastre MTT; Urtasun JA; Abad LP; Hernández IB
Clin Transl Oncol; 2023 May; 25(5):1455-1462. PubMed ID: 36723787
[TBL] [Abstract][Full Text] [Related]
13. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
[TBL] [Abstract][Full Text] [Related]
14. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
[TBL] [Abstract][Full Text] [Related]
15. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Shah MA; Yoshino T; Tebbutt NC; Grothey A; Tabernero J; Xu RH; Cervantes A; Oh SC; Yamaguchi K; Fakih M; Falcone A; Wu C; Chiu VK; Tomasek J; Bendell J; Fontaine M; Hitron M; Xu B; Taieb J; Van Cutsem E
Clin Colorectal Cancer; 2023 Mar; 22(1):100-110. PubMed ID: 36503738
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.
Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
[No Abstract] [Full Text] [Related]
17. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
18. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Franko J; Shi Q; Goldman CD; Pockaj BA; Nelson GD; Goldberg RM; Pitot HC; Grothey A; Alberts SR; Sargent DJ
J Clin Oncol; 2012 Jan; 30(3):263-7. PubMed ID: 22162570
[TBL] [Abstract][Full Text] [Related]
19. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A
JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665
[TBL] [Abstract][Full Text] [Related]
20. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
